A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy

A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy

There are clinical challenges related to adjuvant treatment in colorectal cancer (CRC) and novel molecular markers are needed for better risk stratification of patients. Our aim was to integrate our previously reported clinical-genetic prognostic score with new immunogenetic markers of 5-year diseas...

Full description

Bibliographic Details
Main Authors: Elena De Mattia, Eva Dreussi, Marcella Montico, Sara Gagno, Chiara Zanusso, Luca Quartuccio, Salvatore De Vita, Michela Guardascione, Angela Buonadonna, Mario D’Andrea, Nicoletta Pella, Adolfo Favaretto, Enrico Mini, Stefania Nobili, Loredana Romanato, Erika Cecchin, Giuseppe Toffoli
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-10-01
Series:Frontiers in Pharmacology
Subjects:
colorectal cancer
fluoropyrimidines
interferon-γ
immune system
immunogenetics
adjuvant treatment
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2018.01101/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2018.01101/full

Similar Items